Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
How should abnormal uterine bleeding be managed in people with bleeding disorders: a systematic review of the literature and thematic synthesisRameen Masood, Vidiya Dev, Millie Gee, et al.Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.Scientific Reports|December 3, 2017
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcomeKathleen J Till, John C Allen, Fatima Talab, et al.Trials|August 24, 2017
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Dena R Howard, Talha Munir, et al.Research and Practice in Thrombosis and Haemostasis|October 24, 2018
A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopeniaBen Johnson, Rachel Doak, David Allsup, et al.Small (Weinheim an Der Bergstrasse, Germany)|November 10, 2023
Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with PlateletsHélio M Gil, Zoe Booth, Thomas W Price, et al.Journal of Materials Chemistry. B|December 5, 2024
PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activationLeigh Naylor-Adamson, Thomas W Price, Zoe Booth, et al.Trials|June 29, 2024
Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trialLydia Flett, Radwa Abdelatif, Sarah Akhtar Baz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.The New England Journal of Medicine|December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, David A Cairns, Adrian Bloor, et al.Pageof 5